Medical/Pharmaceuticals
Announcement of the Effect of Ginseng and Red Ginseng for Memory Improvement and Suppression of Bone and Muscle Loss
* Effect of improving blood pressure in patients with high blood pressure and diabetes * Announced at the 13th International Symposium on Ginseng 2022 SEOUL, South Korea, Oct. 31, 2022 /PRNewswire/ -- Experts who have conducted scientific studies on the effect of ginseng gathered inSeoul from...
2022-10-31 21:08
4168
Gracell Biotechnologies to Report Third Quarter 2022 Financials on Monday, November 14, 2022
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Oct. 31, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today ...
2022-10-31 21:00
3035
Senhwa Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer's Talazoparib for the Treatment of Prostate Cancer
TAIPEI and SAN DIEGO, Oct. 31, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced today that their first patient has been successfully dosed, in a phase I c...
2022-10-31 19:00
3336
Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific) in First-line Treatment of ES-SCLC on ACLC 2022
HONG KONG, Oct. 30, 2022 /PRNewswire/ -- Akeso, Biopharma (9926. HK) ("Akeso") released the Phase Ib clinical results of Ivonescimab (PD-1/VEGF bi-specific, AK112) in combination with etoposide and carboplatin in first-line treatment of extensive-stage small-cell lung cancer(ES-SCLC), in an oral ...
2022-10-31 08:40
2397
GenesisCare and PreludeDx(TM) present compelling Australian-first DCISionRT Study Interim Analysis during Breast Cancer Awareness Month 45% change in treatment recommendations when using DCISionRT
CALIFORNIA CITY, Calif., Oct. 30, 2022 /PRNewswire/ -- GenesisCare, a leading provider of integrated cancer care globally, and Prelude Corporation (PreludeDx(TM)), a leader in molecular diagnostics and precision medicine, today announced interim results from the AUSPREDICT registry. Data presente...
2022-10-31 05:00
2115
Nuevocor to Present Pre-clinical Data on its Gene Therapy Candidate for LMNA Dilated Cardiomyopathy at American Heart Association Scientific Sessions 2022
SINGAPORE, Oct. 28, 2022 /PRNewswire/ -- Nuevocor, a pre-clinical stage cardiac gene therapy company, announced today that it will present new preclinical data on its adeno-associated virus (AAV) gene therapy forLMNA dilated cardiomyopathy at the American Heart Association (AHA) Scientific Sessio...
2022-10-28 22:30
3712
LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Meeting 2022
The efficacy and mechanism of NASH microbiome-based therapy for liver fibrosis, steatosis, and inflammation have been confirmed in various animal models SEOUL, South Korea, Oct. 28, 2022 /PRNewswire/ -- LISCure Biosciences, a clinical-stage biopharmaceutical company developing microbe-oriented ne...
2022-10-28 21:00
2812
Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit
BOSTON, Oct. 28, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc. (STAR: 688302), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, today presented their preclinical results of ...
2022-10-28 20:30
3079
NDA for New Second-Line Indication of CAR T-Cell Therapy Product YIKAIDA (Axicabtagene Ciloleucel Injection) Approved for CDE Review
Fosun Kite to Participate in the Fifth CIIE to Showcase New Options in Cell Therapy SHANGHAI, Oct. 27, 2022 /PRNewswire/ -- October 24 brought good news from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) that the NDA for new second-line indication o...
2022-10-28 01:37
3050
WuXi Biologics Provides Corporate Updates
SHANGHAI, Oct. 27, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today updated its recent corporate progress. Recent Business Milestone Despite the global dynamic situation and funding challeng...
2022-10-27 22:13
3581
Simcere Receives FDA Clearance of Investigational New Drug Application (IND) for Bi-functional Fusion Protein, SIM0237
Second US IND approval this year for the global pharmaceutical group NANJING, China and BOSTON, Oct. 27, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK), an innovative global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the com...
2022-10-27 21:25
3112
Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US
SUZHOU, China, Oct. 27, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment and dosing of 120 subj...
2022-10-27 21:22
2978
Antengene to Host Research and Development Day on November 15th and 17th, 2022
* Virtual English Session: Tuesday, November 15 at 8:30 AM – 12:00 PM Eastern Time November 15 at 9:30 PM – November 16 at 1:00 AM Beijing Time * Hybrid Mandarin Session in Shanghai: Thursday, November 17 at 1:30 PM – 5:30 PM Beijing Time SHANGHAI and HONG KONG, Oct. 26, 2022 /PRNewswire/ -- An...
2022-10-27 11:07
4055
Cali Biosciences Announces Publications of Phase IIa Results of Long-Acting Ropivacaine (CPL-01)
CPL-01, for Non-Opioid Treatment of Post-Operative Pain, Garners Publication of Clinical Data in Abdominoplasty and Presentation of Preclinical Data in Bony and Soft-Tissue ModelsSupporting Pharmacokinetics and Safety SAN DIEGO, Oct. 26, 2022 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinaft...
2022-10-27 10:07
2367
Samsung Biologics Reports Third Quarter 2022 Financial Results
* Recorded consolidated revenue of KRW 873 billion in Q3'22 * Recorded consolidated operating profit of KRW 324.7 billion in Q3'22 * Started partial operations at Plant 4 within 23 months since groundbreaking as previously committed and launched two new development platforms INCHEON, South K...
2022-10-27 07:35
2779
Lunit Joins World Economic Forum Global Innovators Community
* Lunit invited to join the World Economic Forum's Global Innovators Community, an invitation-only group of the world's most promising start-ups and scale-ups at the forefront of technological and business model innovation * In 2020, Lunit was nominated among hundreds of candidates as one of t...
2022-10-26 21:00
3419
Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting
MELBOURNE, Australia and SAN FRANCISCO , Oct. 26, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster presentation f...
2022-10-26 19:25
3201
WuXi AppTec Reports Record Year-to-Date Results in 2022, Third Quarter Revenue over RMB10 Billion
Revenue Up 71.9% Year-Over-Year to RMB28,395 Million Net Profit Attributable to Owners of the Company Up 107.1% Year-Over-Year to RMB7,378 Million Diluted Earnings Per Share (EPS) Up 90.1% Year-Over-Year to RMB2.30 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 77.9% Year...
2022-10-26 19:06
4352
Meet the female scientists who develop cellular and gene therapies
SHENZHEN, China, Oct. 26, 2022 /PRNewswire/ -- Inside Namtai Inno Park in Guangming District hides a low-profile biomedical development firm – Shenzhen Wingor Biotechnology Co. Upon entering the company, one may feel a different vibe – something gentle yet vibrant, maybe because it's female-domin...
2022-10-26 17:07
2840
Yiling Pharmaceutical Exhibiting its Innovative TCM Products during CHEXPO Macau 2022
SHIJIAZHUANG, China, Oct. 26, 2022 /PRNewswire/ -- CHEXPO Macau 2022 was officially opened onOctober 20, 2022. As one of the top 10 TCM enterprises in China, Yiling Pharmaceutical exhibited a number of its patented TCM and health products during the expo. As an international and frontier city of ...
2022-10-26 16:52
3035
Week's Top Stories
Most Reposted
MetaOptics Sharpens Focus on Metalens Commercialisation; Withdraws Nasdaq Listing Application, and Defers U.S. Dual Listing Plan
[Picked up by 313 media titles]
2026-08-07 22:30Agoda Launches AI-Powered Room Grid Bot to Help Travelers Decide Which Room to Book
[Picked up by 313 media titles]
2026-08-13 12:00
GCash Parent Mynt Cited as Sole Philippine Firm in World's Top Fintech Companies List
[Picked up by 296 media titles]
2026-08-12 16:02
Two CityUHK scholars elected to the European Academy of Engineering in recognition of their internationally acclaimed research achievements
[Picked up by 294 media titles]
2026-08-10 19:12
MetaOptics Ltd achieves 79% of FY2025 full-year revenue in 1H 2026, on track to fulfil purchase orders of key metalens production equipment in 2H 2026
[Picked up by 293 media titles]
2026-08-11 19:03Most Read
AMTD IDEA's Receipt of NYSE Letter Regarding ADS Trading Price's Below Compliance Standards
2026-08-08 04:01
14603
China Yuchai International Announces Unaudited 2026 First Half-Year Financial Results
2026-08-07 18:00
14347